Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

82.79 USD -0.74 (-0.89%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,169,715
Open 83.26
Bid (Size) 81.00 (1)
Ask (Size) 87.95 (1)
Prev. Close 83.53
Today's Range 81.38 - 83.66
52wk Range 66.20 - 125.61
Shares Outstanding 58,341,527
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
-- First precision therapy that specifically targets the primary driver of the disease -- 
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that, effective on June 1, 2021, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options... 
From PR Newswire

Performance

YTD
-20.83%
-20.83%
1 Month
-13.25%
-13.25%
3 Month
-21.14%
-21.14%
6 Month
-31.96%
-31.96%
1 Year
+5.06%
+5.06%

More News

Read More
Blueprint Medicines to Present at Upcoming Investor Conferences
From PR Newswire
Blueprint Medicines Presents ARROW Trial Data for GAVRETO® (pralsetinib) Highlighting Durable Clinical Activity in Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer and Other Adv
From PR Newswire
Blueprint Medicines Appoints Percy Carter, MBA, Ph.D., as Chief Scientific Officer
From PR Newswire
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From PR Newswire
Blueprint Medicines Reports First Quarter 2021 Financial Results
From PR Newswire
First Week of BPMC August 20th Options Trading
Tags Stocks
From Market News Video
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
From PR Newswire
Analyst Ratings for Blueprint Medicines
Tags Benzinga BZI/AAR Analyst Ratings
From Benzinga
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Tags ETON CYTR Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]